Medicare’s GLOBE model benchmarks drug rebates against 19 countries, none in Latin America

CMS has finalized GLOBE, a mandatory most-favored-nation rebate model for high-spend Medicare Part B drugs starting January 1, 2027. It is far narrower than proposed, faces a PhRMA lawsuit, and benchmarks against 19 wealthy countries that exclude Latin America.

A flat editorial illustration showing a formal pricing scale or balance anchored at the center, with a cluster of geometric country-block shapes arranged in a tight arc on one side and a visually isolated Latin American landmass silhouette floating alone in generous negative space on the other, suggesting exclusion from a structured comparison framework.

DRUG PRICING · PRICE REGULATION · OCTOBER 31, 2026 · UNITED STATES

The Centers for Medicare & Medicaid Services (CMS) on September 30, 2026 finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, a mandatory test of most-favored-nation (MFN) pricing in Medicare Part B, the part of Medicare that pays for drugs given in doctors’ offices and hospital outpatient clinics. The model starts on January 1, 2027; from its first performance year, beginning April 1, 2027, manufacturers of selected high-spend Part B drugs will owe rebates when their US price exceeds a benchmark set by 19 reference countries. None of them is in Latin America.

$440M

Medicare Part B savings CMS now projects from GLOBE over seven years, down from $11.9 billion in the proposed rule, according to Skadden.

What the final rule does

GLOBE covers single-source drugs and sole-source biologics with more than $100 million in annual Part B spending in seven therapeutic classes, including antineoplastics, immunological agents and ophthalmic agents, according to Covington & Burling. Orphan-only drugs, cell and gene therapies on the FDA’s list, plasma-derived products, generics, biosimilars and drugs with a negotiated Medicare price are excluded. The model applies in randomly selected areas covering about 25% of Original Medicare enrollees, with a performance period from April 1, 2027 to March 31, 2032, according to Gibson Dunn. For drugs in scope, the GLOBE rebate sits on top of the existing Part B inflation rebate, which acts as a floor: manufacturers owe only the amount by which the GLOBE rebate exceeds it, according to Goodwin Procter.

The final version is much narrower than the proposal. The start date moved from October 1, 2026 to January 1, 2027, and CMS said it intends to waive mandatory participation in any quarter a manufacturer takes part in the Generating Cost Reductions for U.S. Medicaid (GENEROUS) Model, the voluntary Medicaid most-favored-nation model; its estimates assume waivers for manufacturers that signed by August 17, 2026. Covington says CMS estimates that the waivers cut the number of participating manufacturers from 19 to four, based on an illustrative set of drugs.

Who sets the benchmark

The 19 reference countries are Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, France, Germany, Ireland, Israel, Italy, Japan, the Netherlands, Norway, South Korea, Spain, Sweden, Switzerland and the United Kingdom, according to Gibson Dunn. Covington says the countries must be members of the Organisation for Economic Co-operation and Development (OECD) with real gross domestic product (GDP) per capita of at least 60% of the US level and annual real GDP of at least $400 billion. Reference-country prices are adjusted for differences in GDP measured at purchasing-power parity (PPP), according to Skadden.

No Latin American country meets the income test. On World Bank 2024 data, Chile, the highest-income Latin American OECD member on a PPP basis, has GDP per capita equal to 42% of the US level.

A court test before it starts

The Pharmaceutical Research and Manufacturers of America (PhRMA) sued on October 7 in the US District Court for the District of Columbia (case 1:26-cv-03498), asking the court to declare the model unlawful and vacate it. “CMS cannot rewrite the law and bypass Congress to impose foreign price controls,” PhRMA president and chief executive Stephen Ubl said, as quoted by The American Journal of Managed Care (AJMC). In the final rule, CMS wrote that “disagreement with payment policy does not establish a constitutional violation,” per the same report. The Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model, GLOBE’s companion for Part D prescription drugs, remained under review at the Office of Management and Budget in early October, according to Covington.

For Latin American launch planning, the rule settles one question: prices in the region do not feed the Medicare benchmark. It does not settle the other: Brazil and Colombia include US and European prices in the international reference baskets they use to cap the prices of new or price-controlled drugs, so shifts in those prices can still reach the region through its own rules.

What to Watch

  1. Whether the District of Columbia court rules on PhRMA’s challenge before the January 1, 2027 start
  2. The final GUARD rule for Part D, and whether it mirrors GLOBE’s 19-country basket and waivers
  3. Any move to extend GLOBE beyond the 25% of Original Medicare enrollees in the first phase
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

Sources: Covington & Burling: CMS Finalizes MFN Pricing in Medicare Part B Through GLOBE Model · Gibson Dunn: The GLOBE Final Rule · Skadden: CMS Finalizes the GLOBE Model · AJMC: PhRMA Sues to Block CMS Most Favored Nation Model for Part B · Georgetown Health Care Litigation Tracker: PhRMA v. Kennedy · World Bank: GDP per capita, PPP (2024) · Brazil: CMED Resolution 3 of 2025 · Goodwin: GLOBE MFN Drug Pricing Model Finalized and Scaled Down by CMS · Colombia: Circular 18 of 2024

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related